Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 17/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20801445 | 0.84 | TLR8 (0.53) | TLR8TLR7HPGDMAPK1CSF1R | |
| SCHEMBL19416362 | 0.77 | TLR8 (0.57) | TLR8TLR7HPGDMAPK1CSF1R | |
| SCHEMBL20647703 | 0.76 | TLR8 (0.75) | TLR8TLR7 | |
| SCHEMBL20801509 | 0.76 | TLR8 (0.63) | TLR8TLR7HPGDMAPK1 | |
| SCHEMBL1802374 | 0.76 | TLR8 (0.73) | TLR8TLR7HPGDMAPK1 | |
| SCHEMBL20647672 | 0.76 | TLR8 (0.62) | TLR8TLR7 | |
| SCHEMBL24860058 | 0.76 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL1237666 | 0.75 | TLR8 (0.72) | TLR8TLR7HPGDMAPK1CSF1R | |
| SCHEMBL1588858 | 0.75 | TLR8 (0.71) | TLR8TLR7 | |
| SCHEMBL1237420 | 0.75 | TLR8 (0.50) | TLR8TLR7HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284750-A1 | Immunoconjugate Synthesis Method | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284750-A1 | Immunoconjugate Synthesis Method | FCGR3B, FCGR1A, FCGR2A | TLR8 435/4885TLR7 84/4885HPGD 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.